Biotech Values

[mcbio]

ACHN - 8/19/10 Update Call

http://ir.achillion.com/eventdetail.cfm?eventid=85265

1. Given the significant offering, ACHN expects it can run its existing level of operations through 2012.

2. ACHN will dose the first patient in the Phase 2a trial for ACH-1625 by the end of September.

3. The Phase 2a trial will consist of two cohorts with a total of over 100 patients. The trial will start in the U.S. and also be expanded into Europe. The first cohort will be a 28 day study testing three dose levels of 1625 in combo with pegIFN+riba versus a control of pegIFN+riba. ACHN will obtain RVR @ the 28 day mark and will report this data by the end of 1Q2011. All three 1625 doses will be QD doses and will be either 200mg QD, 400mg QD, or 800mg QD.

The second cohort will follow the same protocol but will be a 12 week study utilizing the two best doses from the first cohort. This data will be reported by YE2011.

4. INDs are expected to be filed for ACH-2684 (3rd gen PI) and ACH-2928 (the NS5A inhibitor) by 1H2011 with PoC data expected by YE2011. ACHN has seen significant synergy between ACH-2928 and 1625.

5. ACHN expects to initiate combo studies of 2928 and 1625 by 2012 and have 28 day Phase 2 PoC data for this combo by YE2012.